At NASMAC, localization is not just a business strategy, it is a national commitment aligned with Saudi Arabia’s Vision 2030 healthcare transformation.
By sharing knowledge, technology and expertise, we empower local terms to share the future of healthcare.
By localizing advanced manufacturing and formulation technologies, NASMAC ensures that high-quality medicines are produced within the Kingdom, reducing dependency on imports and enhancing security of supply.
Our R&D efforts are guided by a single purpose to bridge the gaps left by traditional pharmaceutical models and focus on diseases that truly define the Kingdom’s healthcare landscape.
This includes a strong emphasis on non-communicable diseases (NCDs) such as neuropsychiatric disorders, diabetes, cardiovascular diseases, cancer, obesity, and respiratory conditions (asthma and COPD) all of which have a high prevalence and significant social impact.
NASMAC invests in developing high-quality, affordable, and advanced generic and bio-pharmaceutical formulations. Through strategic partnerships including with Macleods Pharmaceuticals, a global leader in accessible therapeutics. NASMAC leverages international expertise while building local R&D capacity.
For NASMAC, affordability is not about lower prices it is about redefining healthcare as a basic right.
Our therapies are designed to serve as practical lifelines for individuals and families, combining fair pricing with uncompromising quality to help more patients achieve better health outcomes.
To translate this philosophy into action, NASMAC focuses on three strategic pillars:
Developing tailored, affordable, and accessible therapies, leveraging Macleods’ rich portfolio already achieving pre-operational income through active participation in NUPCO tenders.
Strengthening distribution networks across Saudi Arabia and the GCC.
Supporting patient education and prevention initiatives to improve treatment adherence, early detection, and long-term health outcomes.
